Pirfenidone as a Pleiotropic Antifibrotic Agent in Metabolic Steatohepatitis: From Mechanisms to Clinical Evidence
- 30 January 2026
- journal article
- review article
- Published by Elsevier in Archives of Medical Research
- Vol. 57 (4) , 103387
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Implications of liver fibrosis in clinical trialsAnnals of Hepatology, 2025
- Resmetirom: A Breakthrough in the Treatment of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)Health Science Reports, 2025
- Pirfenidone use in fibrotic diseases: What do we know so far?Immunity, Inflammation and Disease, 2024
- Prolonged-release pirfenidone in patients with compensated cirrhosis. Final results of the multicenter study ODISEA, controlled against placebo, plus standardized care_2023Annals of Hepatology, 2024
- Pirfenidone attenuates nonalcoholic fatty liver disease through activation of the nuclear factor erythroid 2‐related factor 2 (Nrf2) signaling pathwayJournal of Biochemical and Molecular Toxicology, 2022
- Multifunctional regulatory protein connective tissue growth factor (CTGF): A potential therapeutic target for diverse diseasesActa Pharmaceutica Sinica B, 2022
- Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO studyHepatology International, 2020
- Functional and structural impact of pirfenidone on the alterations of cardiac disease and diabetes mellitusCell Calcium, 2014
- Hepatic inflammation and fibrosis: Functional links and key pathwaysHepatology, 2014
- Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategiesJournal of Gastroenterology, 2008